RxDoctor Payments Data

David Newton, MD

Gastroenterology · Lincoln, NENPI 1073757217

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $417 and has fallen 63.5% since, to $152 in 2025. That places this record below the midpoint for gastroenterology clinicians in NE, where the typical reported total is $2,374.

$1,594in general payments, 2019–2025

Across 78 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$370
  • Boston Scientific$326
  • Johnson & Johnson$142
  • Olympus America Inc.$112
  • Pfizer$85
  • Bristol Myers Squibb$84
  • plus $474 from 13 others

What the payments were for

  • Food & beverage$1,594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,594 in reported general payments places this provider in the 40th percentile of 89 gastroenterology providers in Nebraska.

See all gastroenterology providers in Nebraska

Medicare billing

Part B allowed, 2024
$330,817
Medicare patients
514
Services billed
9,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid13$122,601
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates280$17,123
CreonLipase/Protease/Amylase11$15,384
LinzessLinaclotide15$11,966
Pantoprazole Sodium221$3,889
Ursodiol27$1,832
Omeprazole116$1,459
Sucralfate22$927
Colestipol Hcl14$900
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl43$769
Dicyclomine Hcl34$688
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl30$518
Azathioprine12$178
Ondansetron Hcl11$114
Prednisone14$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$370$27,35026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 89 gastroenterology providers in Nebraska.

Other gastroenterology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →